Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation-Reference-Cited by-同舟云学术

Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation

Published:2022-02-21 Issue:5 Volume:65 Page:3879-3893
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Tianyu¹,Cai Shi¹,Cheng Yao¹,Zhang Wanheng¹,Wang Minmin¹,Sun Huiyong¹^ORCID,Guo Binghua²,Li Zheng³,Xiao Yibei¹,Jiang Sheng¹^ORCID

Affiliation:

1. State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

2. Syntron Company, Ltd., Yanchen 224500, China

3. Center for Bioenergetics, Houston Methodist Research Institute, 6670 Bertner, Houston, Texas 77030, United States

Funder

Ministry of Education of the People's Republic of China

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c01682

Reference51 articles.

1. Cancer Immunotherapy

2. Cancer immunotherapy: moving beyond current vaccines

3. Cancer immunotherapy comes of age

4. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

5. THE B7 FAMILY REVISITED

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, and optimization of novel PD-L1 inhibitors and the identification of a highly potent and orally bioavailable PD-L1 inhibitor;European Journal of Medicinal Chemistry;2024-11

2. Engineering PD-L1 targeted liposomal canagliflozin achieves multimodal synergistic cancer therapy;Chemical Engineering Journal;2024-10

3. Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors;European Journal of Medicinal Chemistry;2024-10

4. New Advances in the Study of CMTM6, a Focus on Its Novel Non-Canonical Cellular Locations, and Functions beyond Its Role as a PD-L1 Stabilizer;Cancers;2024-09-11

5. Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction;Bioorganic & Medicinal Chemistry;2024-09